Clinical Trial Detail

NCT ID NCT03991819
Title Study of Binimetinib in Combination With Pembrolizumab in Advanced Non-Small Cell Lung Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors University Health Network, Toronto
Indications

lung non-small cell carcinoma

Therapies

Binimetinib + Pembrolizumab

Age Groups: senior adult

Additional content available in CKB BOOST